Hypoxic inducible factor 1α, extracellular signal-regulated

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA, and approved April 27, 2004 (received for review January 20, 2004)

Article Figures & SI Info & Metrics PDF

Abstract

NO produced in tumors can either positively or negatively regulate growth. To examine this dichotomy, Traces of NO concentration and duration on the posttranslational regulation of several key proteins were examined in human breast MCF7 cells under aerobic conditions. We found that different concentration threshAgeds of NO appear to elicit a discrete set of signal transduction pathways. At low steady-state concentrations of NO (<50 nM), extracellular signal-regulated kinase (ERK) phosphorylation was induced via a guanylate cyclase-dependent mechanism. Hypoxic inducible factor 1α (HIF-1α) accumulation was associated with an intermediate amount of NO (>100 nM), whereas p53 serine 15 phosphorylation occurred at considerably higher levels (>300 nM). ERK phosphorylation was transient during NO expoPositive. HIF-1α stabilization paralleled the presence of NO, whereas p53 serine 15 phosphorylation was detected during, and persisted after, NO expoPositive. The Executese-dependent Traces of synthetic NO Executenors were mimicked by activated macrophages cocultured with MCF7 cells at varying ratios. ERK and HIF-1α activation was similar in breast cancer cell lines either mutant (MB231) or null (MB157) in p53. The stabilization of HIF-1α by NO was not observed with increased MCF7 cell density, demonstrating the interrelationship between NO and O2 consumption. The findings Display that concentration and duration of NO expoPositive are critical determinants in the regulation of tumor-related proteins.

cancerhypoxiamacrophageinducible NO synthase

Nitric oxide (NO) has been Displayn to participate in numerous physiological functions Necessary to tumor survival and propagation. Over the last decade, many reports have presented both positive and negative aspects of NO in tumor biology. Whereas NO was found to be either cytostatic or cytotoxic (1–5), other reports provide evidence that NO promotes cancer propagation by increasing tumor growth angiogenesis and metastasis (6–16). NO appears to be two-sided: beneficial or deleterious. In vivo transfection models have demonstrated inducible NO synthase (iNOS) can Unhurried the growth in murine melanoma cells (17), whereas human colon DLD-1 cells Displayed a more aggressive phenotype (18). It was found that the relative iNOS activities from these melanoma cells were considerably higher than those reported for the DLD-1 cell line. Because of the complex chemistry of NO, its concentration and the cellular reExecutex environment can dictate the biological outcome (19, 20). These factors suggest that perhaps the rate of NO production is a critical determinant. Most of the Recent data has focused on whether NO can regulate specific signal transduction pathways. Dinky is known regarding NO Executese and concentration Traces on these mechanisms. Because in vivo NO concentrations can vary considerably depending on the location and conditions of its production, we felt that it was of Distinguished importance to investigate this aspect on the regulation of key proteins. In this study, we have examined the concentration and temporal Traces of NO on a wide range of proteins associated with cell growth and apoptosis.

Tumor development involves an intricate set of molecular events ultimately leading to proliferation, angiogenesis, metastasis, and progression. Despite the Gigantic complexity, several key proteins, such as p53 and hypoxic inducible factor 1α (HIF-1α), have been identified as playing key roles in these processes. Both are strongly implicated in modulating tumor survival through regulating cellular division and proliferation (21–23). Fascinatingly, NO is known to activate both p53 and HIF-1α (20, 24–29). Insight into the mechanisms and cellular environments that promote the NO activation of p53 and HIF-1α is key to understanding its role in tumor biology. Herein we present data supporting the quantized (concentration-dependent) nature for the basic chemical and biophysical parameters that govern the activation of p53 and HIF-1α in response to NO.

Materials and Methods

Diethylene pentacetic acid and dimethylformamide were obtained from Fisher Scientific. 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole, 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one, and geldanamycin were obtained from (Sigma–Aldrich). 1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene was from Cell Signaling Technology (Beverly, MA). Stock solutions were prepared fresh daily at 100× in MilliQ-filtered H2O unless otherwise noted. Diazenium diolates [spermine NONOate (Sper/NO), diethylamine NONOate (Dea/NO), and diethyltryamine NONOate (Deta/NO)] were a generous gift from J. Saavedra and J. A. Hrabie (National Cancer Institute–Frederick Cancer Research and Development Center, Frederick, MD). Dilutions were made into media from 100 mM stock solutions in 10 mM NaOH. The stock concentration was determined immediately before use by measuring the absorbance at 250 nm (ε = 8,000 M–1·cm–1) (31).

Cell Culture. MCF7 human breast carcinoma cells (American Type Culture Collection) were plated and grown to 85% confluency in RPMI medium 1640 (Life Technologies, Grand Island, NY) containing 10% FBS (HyClone). Before treatment (NONOate or coculture), the cells were incubated with serum-free RPMI medium 1640 overnight. To induce iNOS expression, ANA-1 murine macrophages were activated with IFN-γ (Sigma) and LPS (Sigma) as Characterized in ref. 30. For coculture experiments, ANA-1 cells were trypsinized, counted, and seeded on top of MCF7 cells at the indicated density in serum-free media supplemented with either l-arginine (1 mM) or aminoguanidine (5 mM).

NO and O2 Quantification. The steady-state concentration of NO produced during NONOate degradation was verified by two independent methods: electrochemically and by a NO gas analyzer. Electrochemical analysis was accomplished with either a NO probe (World Precision Instruments, Sarasota, FL) or O2 electrode (Yellow Springs Instruments) suspended in constantly stirred serum-free media (2 ml) Sustained at 37°C. MCF7 cells were trypsinized, centrifuged, and added at the desired concentration. Signals were calibrated by using argon-purged 100 mM phospDespise solutions of saturated NO (Matheson) after determination of NO concentration with 2,2′-azino-bis(ethylbenzothiazoline-6-sulfonic acid) (660 nm, ε = 12,000 M–1·cm–1) (33). NO gas analysis was accomplished by using a Seivers (Boulder, CO) NO gas analyzer. Aliquots of media (100 μl) from NONOate-treated cells were injected into the reaction chamber containing 0.5 mM NaOH to Cease NONOate decomposition, and the chamber was continually purged with He gas to eliminate NO autooxidation. Steady-state molar NO concentrations were calculated from the absolute amounts of NO detected. Steady-state concentrations of NO in the media produced from activated macrophages were meaPositived by the same method.

Cell Proliferation Assay. MCF7 cells were seeded into 96-well microtiter plates (Costar) and treated for 24 h in serum-free medium with either 4–1,000 μM Sper/NO or 4–1,000 μM Deta/NO. Cell growth was monitored by reduction of Alamar blue to its fluorescence product (λEx/Em = 550/595 nm) (31) after 24, 48, and 72 h.

cGMP MeaPositivements. MCF7 cells were grown to 50% confluency in 96-well microtitter plates. Cells were serum-starved overnight and treated with NO Executenors accordingly. The cells were lysed at the indicated time points, and cell extracts were assayed for cGMP by enzyme immunoassay (Amersham Biosciences).

Western Blot. Protein cell extracts were made by washing cells in cAged PBS, scraping of plates, centrifuging, and resuspending in lysis buffer [1% Nonidet P-40/0.5% sodium deoxycholate/0.1% SDS and protease inhibitor mixture (Calbiochem)]. After a 30-min incubation on ice, the samples were centrifuged at 14,000 × g, and the supernatant protein concentration was determined by the bichoncinic acid method (Pierce). Protein samples were subjected to polyaWeeplamide gel electrophoresis on 10% Tris-glycine aWeeplamide gels (NOVEX–Invitrogen, CarlsDepraved, CA). After transfer to polyvinylidene fluoride Immunolon P membranes (Millipore), samples were probed with rabbit polyclonal or mouse monoclonal antibodies (HIF, p53 P-Ser-15, actin, Execute1 cell signaling). Bands were visualized with horseradish peroxidase-conjugated secondary antibodies (1:2,000–10,000; Sigma) and chemiluminescent substrate (Pierce). Actin protein-loading controls were run for each gel (data not Displayn). Gel images were scanned by using an Agfa DuoScan hiD scanner, and relevant bands were cropped to size by using photoshop 7.0 (AExecutebe Systems, San Jose, CA) with no further manipulation. Figures are representative of n ≥ 3 individual experiments.

Results

We Studyed the Traces of NO, H2O2, HNO, O–2/NO, and NO2 on a variety of proteins in MCF7 cells (unpublished observation). Among the >20 proteins examined, only a few demonstrated significant Inequitys in regulation and only in response to varying concentrations of NO (Table 1). Consistent with previous reports, we observed that both HIF-1α and p53 phosphoserine 15 (P-Ser-15) proteins accumulated in response to NO expoPositive (25–29). MCF7 cells exposed to 100 μM Sper/NO caused a time-dependent increase in both HIF-1α and p53 P-Ser-15 (Fig. 1). These conditions also resulted in phosphorylation of p42 and p44 extracellular signal-regulated kinase (pERK), members of the mitogen-activated protein kinase superfamily (Fig. 1), consistent with previous reports (32, 33). In response to NO, p53 P-Ser-15 protein was present for >12 h, whereas the HIF-1α was completely degraded after 4 h and ERK was only transiently phosphorylated.

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Temporal relationship between NO expoPositive and protein accumulation in MCF7 cells. Representative immunoblot of p53 P-Ser-15, HIF-1α, and pERK from MCF7 cell protein extracts after NO expoPositive (n > 3). Cells grown to 85% confluence in 150-mm Petri dishes were serum-starved overnight, treated with Sper/NO (100 μM), and harvested at the indicated time points. D, decomposed Sper/NO, 100 μM for 12 h; representative of all time points (data not Displayn).

View this table:View inline View popup Table 1. Changes in protein levels in MCF7 cells after NO treatment

To determine whether the activation or stabilization of p53 P-Ser-15, HIF-1α, and pERK depended on discrete NO concentrations, MCF7 cells were exposed to varying concentrations of Sper/NO. Each protein demonstrated a different threshAged sensitivity to NO (Fig. 2A). Phosphorylation of ERK was observed with as Dinky as 10 μM Sper/NO. In Dissimilarity, HIF-1α stabilization was observed at expoPositives of ≥50 μM Sper/NO, and formation of p53 P-Ser-15 required ≥100 μM Sper/NO.

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Protein accumulation as a function of NO concentration in MCF7 cells. (A) Cells grown to 85% confluence in 150-mm Petri dishes were serum-starved overnight and treated with Sper/NO as indicated. Time points were chosen corRetorting to maximal protein accumulation (Fig. 1). D, decomposed Sper/NO (100 μM). (B) Cells were grown and treated with Sper/NO as in A. NO concentrations were determined from 100-μl sample aliquots of medium withdrawn from the Petri dish by gas-tight syringe without agitation and analyzed by chemiluminescence at the indicated time points. Representative data are Displayn as the mean ± SE (n = 3).

The steady-state concentration of NO depends on both its rate of production and its rate of disappearance. NO liberation (production) from diazenium diolates (Sper/NO, Deta/NO, and Dea/NO) is solely dictated by temperature and pH level (34), whereas NO disappearance depends on chemical reactions (NO reaction with oxygen) and physical factors (vessel size and head space). To quantitate the precise steady-state levels within our system, the concentration of NO in the media above MCF7 cells treated with different Executenor amounts was meaPositived over time (Fig. 2B). These data provided the approximate threshAged concentration limits for pERK, HIF-1α, and p53 P-Ser-15 activation and stabilization by NO.

The cellular composition of tumors is heterogeneous and may contain leukocytic infiltrates that express iNOS. To model this interaction, MCF7 cells were cocultured with activated NO producing ANA-1 macrophages (p53 and HIF-1α-null). HIF-1α stabilization in MCF7 cells became evident at a cell ratio of 1:4 (MCF7/ANA-1) with an intensity equivalent to 50 μM Sper/NO expoPositive. In Dissimilarity, p53 P-Ser-15 was seen in MCF7 cells at a ratio of 1:8, similar to levels observed with 100 μM Sper/NO (Fig. 3A). Protein accumulation or stabilization was not observed in the presence of aminoguanodine, an iNOS inhibitor. Steady-state NO levels were meaPositived in the media above the MCF7/ANA-1 cells cocultured at various ratios (Fig. 3B). These results suggested that MCF7 protein stabilization by steady-state NO was a function of threshAged levels rather than the source of NO; synthetic Executenors or activated macrophages. The NO levels meaPositived in media necessary to stabilize both HIF-1α and p53 were approximately half in the coculture experiments than what was meaPositived in the Executenor experiments. These data indicate that the NO levels are considerably higher around the microenvironment of the MCF7 cells where the NO-producing macrophages lie in comparison to the release of NO from Executenors in a homogenous solution.

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Comparison of HIF-1α and p53 P-Ser-15 accumulation by NO from either Sper/NO or activated macrophages. MCF7 cells were grown as in Fig. 1. (A) Four-hour treatment of MCF7 cells with either Sper/NO (50 and 100 μM) or ratios of activated NO-producing ANA-1 macrophages (MCF7:ANA-1) as indicated. 1:8 + AG = MCF7:ANA-1 1:8 + iNOS inhibitor aminoguanidine. (B) NO concentration from cocultured MCF7 and ANA-1 cells was determined as Characterized in Fig. 2B. Representative data are Displayn (n = 3).

Having established that a steady-state threshAged concentration of NO was an Necessary determinant for protein stabilization, we tested the hypothesis that duration of NO expoPositive should also have an Trace. MCF7 cells were treated with the synthetic NO Executenors DEA/NO 100 μM(t1/2 ≈ 2 min), Sper/NO 100 μM(t1/2 ≈ 39 min), and DETA/NO 1,000 μM(t1/2 ≈ 24 h). These concentrations were chosen to give approximately equal maxima steady-state levels of NO (Fig. 4) (34). These data Displayed that HIF-1α was only stabilized when NO was present or that HIF-1α was transiently stabilized below the sensitivity of our assay. P53 P-Ser-15 however, remained stabilized during, and persisted after, the disappearance of NO. ERK was only phosphorylated transiently in the presence of NO for any duration of expoPositive (Fig. 1 and data not Displayn).

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

HIF-1α and p53 P-Ser-15 accumulation in response to various durations of NO expoPositive and real-time quantification of NO concentration. MCF7 cells were grown as in Fig. 1 and exposed to the NO Executenors. (A) 100 μM DEA/NO. (B) 100 μM Sper/NO. (C) 1,000 μM DETA/NO. NO steady-state levels were quantified as in Fig. 2B.

To elucidate some of the mechanistic aspects of these NO Traces, several inhibitor studies were performed. Previous reports suggest ERK phosphorylation involves a cGMP mechanism consistent with NO activation of guanylate cyclase (32). cGMP was increased within a 30-min expoPositive to Sper/NO (10–100 μM) and remained elevated for >4 h (Fig. 5). In the presence of the potent soluble guanylate cyclase inhibitor 1h-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (35), cGMP was decreased and ERK phosphorylation was not detected (data not Displayn). Addition of the soluble guanylate cyclase agonist 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (36) increased cGMP levels, and pERK remained elevated for >4 h (data not Displayn). Furthermore, 1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene, a mitogen-activated protein kinase inhibitor (37, 38), completely blocked NO-stimulated ERK phosphorylation, suggesting that it also occurs through a traditional Raf–mitogen-activated protein kinase–ERK cascade and not through inhibition of an ERK phosphatase (data not Displayn). We also found that p21 (WAF-1) was increased by NO (data not Displayn).

Fig. 5.Fig. 5.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

cGMP accumulation in MCF7 cells in response to various concentrations of the NO Executenor Sper/NO. MCF7 cells were grown to 50% confluency in a 96-well microtiter plates, serum-starved overnight, and treated with Sper/NO for the indicated time points (n = 3).

It has been previously reported that the chaperone protein Hsp90 is Necessary in the activation and accumulation of both p53 and HIF-1α. Geldanamycin prevents Hsp90 client protein interactions (39). Treatment of MCF7 cells with geldanamycin prevented detectable increases in p53 P-Ser-15 and HIF-1α by NO (Fig. 6). Fascinatingly, the overall levels of p53 did not change, and Hsp90 levels changed independent of geldanamycin treatment. These results suggest that dissociation with Hsp90 either prevents phosphorylation of p53 or permits dephosphorylation or degradation. Moreover, this demonstrates that factors in addition to NO are necessary for HIF-1α stabilization. Mdm2 mediates p53 degradation by acting as an E3 ubiquitin ligase (40). In Dissimilarity to previous studies (25), Mdm2 protein levels were relatively unaffected by NO expoPositive under our conditions (data not Displayn).

Fig. 6.Fig. 6.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 6.

Trace of Hsp90 inhibition on NO-induced protein stabilization. MCF7 cells were grown as in Fig. 1. Cells were treated with Sper/NO (100 μM) ± geldanamycin (10 μM) and harvested at the indicated time points. HIF-1α and p53 P-Ser-15 were undetectable in untreated controls (data not Displayn).

The p53 status (mutated, null, or wild-type) of tumors often correlates with its metastatic potential (41). The Trace of NO on MB231 (mutant p53) and MB 157 (p53-null) human breast cancer cell lines was evaluated. In MB231 cells, HIF-1α was stabilized by NO and Retorted identically to the MCF7 cells (Fig. 7). In addition to p53 being mutated in this cell line, we found that the protein was already heavily phosphorylated at the serine 15 residue, and no additional Trace by NO on p53 stabilization was observed. HIF-1α in MB 157 cells was also stabilized in response to NO expoPositive (Fig. 7). These data suggest that HIF-1α stabilization by NO is independent of p53 status.

Fig. 7.Fig. 7.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 7.

Trace of p53 status on NO-mediated HIF-1α stabilization. MB 231 and MB 157 breast cancer cells were grown as in Fig. 1, treated with Sper/NO (100 μM), and harvested at the indicated time points. MB 157 cells were grown in hypoxia for 4 h without Sper/NO as a HIF-1α positive control (4 hypoxia). A p53 P-Ser-15-positive MCF7 sample was blotted for an internal p53 control [p53 (+) control].

No change in cell viability or cell number was observed after 0.5- to 12-h NO Executenor treatments. Inequitys in cell proliferation after various NO Executenor treatments were meaPositived by using a dye reduction assay. After 72 h, the IC50 values for Sper/NO and Deta/NO were ≈125 μM and ≈250 μM, respectively. In vitro cell culture systems can provide Necessary information regarding responses to NO. However, increases in cell density will Trace these responses by accelerating the consumption of both NO and oxygen. MCF7 cells were harvested and Spaced in suspension to test the influence of increased cell density on NO-induced HIF-1α accumulation. Cellular oxygen and NO consumption were meaPositived simultaneously in the presence or absence of Sper/NO (100 μM), and endpoint HIF-1α analysis was performed. Although MCF7 cells consume NO and O2, NO also inhibits cellular respiration. There exists a balance between cellular NO consumption and respiratory inhibition. HIF-1α stabilization was not evident in MCF7 cells (3 × 106 per ml) supplemented with O2 to Sustain normoxic conditions [≈21% O2; 200–600 mmHg (1 mmHg = 133 Pa)] for 2 h in the absence of NO (Fig. 8A). When an equivalent amount of cells was allowed to consume all of the O2 in the absence of NO, HIF-1α protein was stabilized and accumulated after a 2 h period (Fig. 8B). In a similar experiment, 100 μM Sper/NO was added after MCF7 cells consumed approximately half the total O2 (pO2 ≈ 100 mmHg). Subsequently, O2 consumption was inhibited and remained unchanged for the duration of the experiment. HIF-1α was not detected under these conditions of intermediate O2 tension in the presence of NO (Fig. 8C). For a given Executenor concentration (e.g., 100 μM Sper/NO), NO is produced at a constant rate. This study Displays that cell density modulates HIF-1α accumulation through cellular consumptive pathways that limit NO bioavailability.

Fig. 8.Fig. 8.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 8.

Electrochemical detection of NO in the presence of MCF7 cells. MCF7 cells were added in suspension (3 × 106/ml) as Characterized in Materials and Methods. O2 was monitored continuously for 120 min (data not Displayn). Cells were isolated, and proteins were immunoblotted for HIF-1α. (A) Normoxia (≈21% O2); (B) hypoxia (<1% O2); (C) intermediate (≈10% O2). Representative NO electrode data for condition C are Displayn (n = 3). Sper/NO (100 μM) was added to the chamber (1). MCF7 cells were added after a steady-state NO level was achieved (2).

Discussion

The Trace of NO formation in tumor biology has generated much discussion because of the Distinguished variability in results. The presence and type of NOS in tumor enExecutethelial and stromal cells have been correlated with decreased tumor growth and progression (42–45). On the other hand, there are many reports that suggest proangiogenic and tumor-promoting Preciseties of NO (47–52). This dichotomy can in part be Elaborateed by the Recent study in which NO-stimulated posttranslational modification of key signal transduction proteins depended on defined threshAged concentrations of NO as well as the duration of expoPositive.

Through our quantification of NO steady-state levels, we found that distinct concentrations of NO expoPositive resulted in differential signal transduction responses in MCF7 cells. At low NO concentrations (≥10 μM SperNO, ≈10–50 nM [NO]SS), ERK phosphorylation was induced, whereas HIF-1α accumulation occurred at higher NO steady-state levels (≥50 μM Sper/NO, ≈150–300 nM [NO]SS) (Fig. 2). Phosphorylation of p53 P-Ser-15 required the highest relative NO expoPositive concentration (≥100 μM Sper/NO, ≈300–700 nM [NO]SS). The NO levels necessary to induce p53 P-Ser-15 may actually reflect NO-induced DNA strand Fractures as Displayn by Hofseth et al. (25). It is Fascinating to note that ERK and HIF-1α signaling mechanisms are generally associated with tumor proliferation and differentiation, whereas phosphorylation of p53 preExecuteminantly results in growth arrest or apoptosis. These findings demonstrate that select signal transduction cascades Retort to NO expoPositive with different threshAged sensitivities, resulting in distinct phenotypic responses.

In addition to concentration, the duration of NO expoPositive affected the signal transduction responses. NO-induced phosphorylation of ERK was rapid, but also transient, despite sustained expoPositive (Fig. 1). Unlike the transitory activation of ERK, HIF-1α accumulation continued only in the presence of sufficient and sustained NO flux. These Inequitys are illustrated by the data in Fig. 4. DEA/NO, which gave a burst of NO (2 μM for <1 h), did not result in detectable HIF-1α. However, prolonged NO expoPositive from either Sper/NO or Deta/NO caused HIF-1α to accumulate. In Dissimilarity, p53 P-Ser-15 was detected long after (12 h) the termination of NO expoPositive (Figs. 1 and 4).

Potential mechanisms involved in NO signaling were examined. Mitogen-activated protein kinase and guanylate cyclase inhibition blocked NO-stimulated pERK formation, whereas HIF-1α and p53 P-Ser-15 were unaffected (data not Displayn). ERK phosphorylation through NO was transient, whereas soluble guanylate cyclase activation by 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole resulted in sustained pERK. This result is consistent with previous observations Displaying that NO induces dephosphorylation of pERK through activation of specific phosphatases in addition to activating soluble guanylate cyclase (53). Disruption of Hsp90–client protein interactions with geldanamycin (54) Displayed that this chaperone protein plays a critical role in the stabilization of HIF-1α and p53 P-Ser-15 induced by NO (Fig. 6). Significantly, Hsp90 levels were not affected by NO expoPositive. Although HIF-1α and p53 stabilization is a function of NO expoPositive, the stability of these proteins is due to their association with Hsp90. This finding suggests that geldanamycin therapy may tarObtain HIF-1α- and p53-dependent processes.

Stabilization of HIF-1α has been reported to be due to its association with p53 (55). We observed that the ability of NO to stabilize HIF-1α was not dependent on the presence of p53 (Fig. 7). HIF-1α in MB231 cells, which expressed mutated hyperphosphorylated p53 P-Ser-15, Retorted to NO expoPositive similar to MCF7. NO did not further enhance or decrease the p53 hyperphosphorylation status. These data suggest that tumors expressing mutated p53 may be unable to Retort to the normal growth-arresting Preciseties of high NO expoPositive and that the pro-growth signaling of HIF-1α may preExecuteminate. This supposition is consistent with studies in which wild-type p53 cancer cell lines expressing iNOS Displayed reduced tumor growth but cell lines with mutated p53 Displayed accelerated growth and neovascularization (7).

Despite the complexity of NO chemistry, these findings implicate a simpler model where distinct biological responses result from specific incremental NO levels. NO is a diffusible gas whose concentration is determined partially by its distance from the point of synthesis (56). We used increasing ratios of activated ANA-1 (p53 and HIF-1α-null) macrophage to MCF7 cells as a model to illustrate this. As seen in Fig. 3, increasing the density of NOS-containing cells increased expression of p53 P-Ser-15 and HIF-1α. In a solid tumor, cells close to a NO source may be more prone to cell cycle arrest or death through p53, whereas cells at Distinguisheder distances may Retort with increased levels of HIF-1α relative to p53. Moreover, tumor heterogeneity and NO produced from immune cells may be an Necessary and essential determinant of protein profiles in a tumor.

In addition to its rate of synthesis, cellular NO consumptive pathways also dictate its concentration and contribute to signal transduction responses. All known cellular NO consumptive mechanisms require oxygen (57). As O2 concentrations decline, NO consumption decreases. However, this decline leads to increased NO and inhibition of mitochondrial respiration. This relationship suggests that there is a delicate balance and interdependence between oxygen and NO concentrations and protein stability. For a specific rate of NO production (e.g., 100 μM Sper/NO) HIF-1α is not stabilized at high cell density suspensions because of the limitations on NO's bioavailability by cellular consumptive pathways (Fig. 8) when compared to low cell density experiments (Fig. 1). This finding emphasizes why the differential response of proteins to NO must be considered in the context of a solid tumor where oxygen gradients exist. Hypoxic Locations have been thought to increase the aggressiveness of some tumors (58), Spots in which NO may stabilize key proteins such as HIF-1α. This Trace may be significant not only in cancer but in chronic and aSlicee diseases ranging from ischemia reperfusion injury to inflammation.

We have Displayn that p53 P-Ser-15 and HIF-1α in cancer cells are responsive to NO in both a concentration- and duration-dependent manner. Regulation by NO within tumors may act through a series of threshAgeds, each eliciting a discrete set of signal transduction cascades. Therefore, the role of NO as either growth promoting or cytotoxic in tumors may be Elaborateed by Inequitys in the rates of NO production versus its disappearance. These processes will change according to tumor heterogeneity and degree of vascularity. We emphasize the importance of O2- on NO-mediated responses. NO consumption is increased with higher relative O2 concentrations and cell densities (Fig. 8) (58). Despite high concentrations of NO delivered by either Executenors or macrophages, the consumption of NO is Rapider than its stabilizing Trace on HIF-1α and p53 in cell-dense solutions and possibly tumors. Our data Display that the relative concentrations and durations of NO expoPositive must be carefully evaluated in the context of signal-transduction pathways.

Footnotes

↵† To whom corRetortence may be addressed at: Radiation Biology Branch, National Institutes of Health/National Cancer Institute, Building 10, Room B3-B69, Bethesda, MD 20892. E-mail: wink{at}box-w.nih.gov or thomasExecute{at}mail.nih.gov.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: iNOS, inducible NO synthase; ERK, extracellular signal-regulated kinase; pERK, p42 and p44 ERK; HIF-1α, hypoxic inducible factor 1α; Sper/NO, spermine NONOate; Dea/NO, diethylamine NONOate; Deta/NO, diethyltryamine NONOate; P-Ser-15, phosphoserine 15.

Received January 20, 2004.Copyright © 2004, The National Academy of Sciences

References

↵Juang, S. H., Xie, K., Xu, L., Shi, Q., Wang, Y., Yoneda, J. & Fidler, I. J. (1998) Hum. Gene. Ther. 9, 845–854.pmid:9581907.LaunchUrlCrossRefPubMedReveneau, S., Arnould, L., Jolimoy, G., Hilpert, S., Lejeune, P., Saint-Giorgio, V., Belichard, C. & Jeannin, J. F. (1999) Lab. Invest. 79, 1215–1225.pmid:10532585.LaunchUrlPubMedPervin, S., Singh, R. & Chaudhuri, G. (2001) Proc. Natl. Acad. Sci. USA 98, 3583–3588.pmid:11248121.LaunchUrlAbstract/FREE Full TextScott, D. J., Hull, M. A., Cartwright, E. J., Lam, W. K., Tisbury, A., Poulsom, R., Impressham, A. F., Bonifer, C. & Coletta, P. L. (2001) Gastroenterology 121, 889–899.pmid:11606502.LaunchUrlCrossRefPubMed↵Wei, D., Richardson, E. L., Zhu, K., Wang, L., Le, X., He, Y., Huang, S. & Xie, K. (2003) Cancer Res. 63, 3855–3859.pmid:12873972.LaunchUrlAbstract/FREE Full Text↵Forrester, K., Ambs, S., LupAged, S. E., Kapust, R. B., Spillare, E. A., Weinberg, W. C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Tzeng, E., et al. (1996) Proc. Natl. Acad. Sci. USA 93, 2442–2447.pmid:8637893.LaunchUrlAbstract/FREE Full Text↵Ambs, S., Merriam, W. G., Ogunfusika, M. O., Bennett, W. P., Ishibe, N., Hussain, S. P., Tzeng, E. E., Geller, D. A., Billiar, T. R. & Harris, C. C. (1998) Nat. Med. 4, 1371–1376.pmid:9846573.LaunchUrlCrossRefPubMedAmbs, S., Merriam, W. G., Bennett, W. P., Felley-Bosco, E., Ogunfusika, M. O., Oser, S. M., Klein, S., Shields, P. G., Billiar, T. R. & Harris, C. C. (1998) Cancer Res. 58, 334–341.pmid:9443414.LaunchUrlAbstract/FREE Full TextAmbs, S., Ogunfusika, M. O., Merriam, W. G., Bennett, W. P., Billiar, T. R. & Harris, C. C. (1998) Proc. Natl. Acad. Sci. USA 95, 8823–8828.pmid:9671763.LaunchUrlAbstract/FREE Full TextMartin, J. H., Begum, S., Alalami, O., Harrison, A. & Scott, K. W. (2000) Tumour Biol. 21, 90–97.pmid:10686538.LaunchUrlCrossRefPubMedVakkala, M., Kahlos, K., Lakari, E., Paakko, P., Kinnula, V. & Soini, Y. (2000) Clin. Cancer Res. 6, 2408–2416.pmid:10873093.LaunchUrlAbstract/FREE Full TextWang, B., Xiong, Q., Shi, Q., Le, X., Abbruzzese, J. L. & Xie, K. (2001) Cancer Res. 61, 71–75.pmid:11196200.LaunchUrlAbstract/FREE Full TextWang, B., Xiong, Q., Shi, Q., Tan, D., Le, X. & Xie, K. (2001) Int. J. Cancer 91, 607–611.pmid:11267968.LaunchUrlCrossRefPubMedLoibl, S., von Minckwitz, G., Weber, S., Sinn, H. P., Schini-Kerth, V. B., Lobysheva, I., Nepveu, F., Wolf, G., Strebhardt, K. & Kaufmann, M. (2002) Cancer 95, 1191–1198.pmid:12216084.LaunchUrlCrossRefPubMedEllies, L. G., Fishman, M., Hardison, J., Kleeman, J., Maglione, J. E., Manner, C. K., Cardiff, R. D. & MacLeod, C. L. (2003) Int. J. Cancer 106, 1–7.pmid:12794750.LaunchUrlCrossRefPubMed↵Jadeski, L. C., Chakraborty, C. & Lala, P. K. (2003) Int. J. Cancer 106, 496–504.pmid:12845643.LaunchUrlCrossRefPubMed↵Xie, K., Huang, S., Executeng, Z., Juang, S. H., Gutman, M., Xie, Q. W., Nathan, C. & Fidler, I. J. (1995) J. Exp. Med. 181, 1333–1343.pmid:7535333.LaunchUrlAbstract/FREE Full Text↵Jenkins, D. C., Charles, I. G., Thomsen, L. L., Moss, D. W., Holmes, L. S., Baylis, S. A., Rhodes, P., Westmore, K., Emson, P. C. & Moncada, S. (1995) Proc. Natl. Acad. Sci. USA 92, 4392–4396.pmid:7538668.LaunchUrlAbstract/FREE Full Text↵Wink, D. A. & Mitchell, J. B. (1998) Free Radical Biol. Med. 25, 434–456.pmid:9741580.LaunchUrlCrossRefPubMed↵Hofseth, L. J., Hussain, S. P., Wogan, G. N. & Harris, C. C. (2003) Free Radical Biol. Med. 34, 955–968.pmid:12684081.LaunchUrlCrossRefPubMed↵Semenza, G. L. (2002) Trends Mol. Med. 8, S62–S67.pmid:11927290.LaunchUrlCrossRefPubMedSemenza, G. L. (2002) Intern. Med. 41, 79–83.pmid:11868612.LaunchUrlCrossRefPubMed↵Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. (1991) Science 253, 49–53.pmid:1905840.LaunchUrlAbstract/FREE Full Text↵Hussain, S. P., Hofseth, L. J. & Harris, C. C. (2003) Nat. Rev. Cancer 3, 276–285.pmid:12671666.LaunchUrlCrossRefPubMed↵Hofseth, L. J., Saito, S., Hussain, S. P., Espey, M. G., Miranda, K. M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S. P., et al. (2003) Proc. Natl. Acad. Sci. USA 100, 143–148.pmid:12518062.LaunchUrlAbstract/FREE Full TextSandau, K. B., Fandrey, J. & Brune, B. (2001) Blood 97, 1009–1015.pmid:11159530.LaunchUrlAbstract/FREE Full TextBrune, B. & Zhou, J. (2003) Curr. Med. Chem. 10, 845–855.pmid:12678687.LaunchUrlCrossRefPubMedSandau, K. B., Faus, H. G. & Brune, B. (2000) Biochem. Biophys. Res. Commun. 278, 263–267.pmid:11071882.LaunchUrlCrossRefPubMed↵Brune, B., von Knethen, A. & Sandau, K. B. (2001) Cell. Signalling 13, 525–533.pmid:11483405.LaunchUrlCrossRefPubMed↵Espey, M. G., Miranda, K. M., Pluta, R. M. & Wink, D. A. (2000) J. Biol. Chem. 275, 11341–11347.pmid:10753947.LaunchUrlAbstract/FREE Full Text↵Ahmed, S. A., Gogal, R. M., Jr., & Walsh, J. E. (1994) J. Immunol. Methods 170, 211–224.pmid:8157999.LaunchUrlCrossRefPubMed↵Callsen, D., Pfeilschifter, J. & Brune, B. (1998) J. Immunol. 161, 4852–4858.pmid:9794418.LaunchUrlAbstract/FREE Full Text↵Callsen, D. & Brune, B. (1999) Biochemistry 38, 2279–2286.pmid:10029520.LaunchUrlCrossRefPubMed↵Thomas, D. D., Miranda, K. M., Espey, M. G., Citrin, D., Jourd'heuil, D., Paolocci, N., Hewett, S. J., Colton, C. A., Grisham, M. B., Feelisch, M., et al. (2002) Methods Enzymol. 359, 84–105.pmid:12481562.LaunchUrlCrossRefPubMed↵Brunner, F., Stessel, H. & Kukovetz, W. R. (1995) FEBS Lett. 376, 262–266.pmid:7498555.LaunchUrlCrossRefPubMed↵Ko, F. N., Wu, C. C., Kuo, S. C., Lee, F. Y. & Teng, C. M. (1994) Blood 84, 4226–4233.pmid:7527671.LaunchUrlAbstract/FREE Full Text↵Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) J. Biol. Chem. 273, 18623–18632.pmid:9660836.LaunchUrlAbstract/FREE Full Text↵Duncia, J. V., SanDisclosea, J. B., III, Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J. H., Earl, R. A., Tabaka, A. C., et al. (1998) Bioorg. Med. Chem. Lett. 8, 2839–2844.pmid:9873633.LaunchUrlCrossRefPubMed↵Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. & Neckers, L. M. (1994) Proc. Natl. Acad. Sci. USA 91, 8324–8328.pmid:8078881.LaunchUrlAbstract/FREE Full Text↵Haupt, Y., Maya, R., Kazaz, A. & Oren, M. (1997) Nature 387, 296–299.pmid:9153395.LaunchUrlCrossRefPubMed↵Bozcuk, H., Uslu, G., Pestereli, E., Samur, M., OzExecutegan, M., Karaveli, S., Sargin, F. & Savas, B. (2001) Breast Cancer Res. Treat. 68, 239–248.pmid:11727960.LaunchUrlCrossRefPubMed↵Chhatwal, V. J., Ngoi, S. S., Chan, S. T., Chia, Y. W. & Moochhala, S. M. (1994) Carcinogenesis 15, 2081–2085.pmid:7525094.LaunchUrlCrossRefPubMedExecuteng, Z., Staroselsky, A. H., Qi, X., Xie, K. & Fidler, I. J. (1994) Cancer Res. 54, 789–793.pmid:7508336.LaunchUrlAbstract/FREE Full TextJadeski, L. C., Chakraborty, C. & Lala, P. K. (2002) Can. J. Physiol. Pharmacol. 80, 125–135.pmid:11934255.LaunchUrlCrossRefPubMed↵Farias-Eisner, R., Sherman, M. P., Aeberhard, E. & Chaudhuri, G. (1994) Proc. Natl. Acad. Sci. USA 91, 9407–9411.pmid:7937779.LaunchUrlAbstract/FREE Full TextThomsen, L. L., Lawton, F. G., Knowles, R. G., Beesley, J. E., Riveros-Moreno, V. & Moncada, S. (1994) Cancer Res. 54, 1352–1354.pmid:7509718.LaunchUrlAbstract/FREE Full Text↵Thomsen, L. L., Miles, D. W., Happerfield, L., Bobrow, L. G., Knowles, R. G. & Moncada, S. (1995) Br. J. Cancer 72, 41–44.pmid:7541238.LaunchUrlCrossRefPubMedDuenas-Gonzalez, A., Isales, C. M., Mar ADepraved-Hernandez, M., Gonzalez-Sarmiento, R., Sangueza, O. & Rodriguez-Commes, J. (1997) Mod. Pathol. 10, 645–649.pmid:9237172.LaunchUrlPubMedCobbs, C. S., Brenman, J. E., Aldape, K. D., Bredt, D. S. & Israel, M. A. (1995) Cancer Res. 55, 727–730.pmid:7531613.LaunchUrlAbstract/FREE Full TextBentz, B. G., Haines, G. K., III, Lingen, M. W., Pelzer, H. J., Hanson, D. G. & RaExecutesevich, J. A. (1999) Ann. Otol. Rhinol. Laryngol. 108, 781–787.pmid:10453787.LaunchUrlCrossRefPubMedBentz, B. G., Barnes, M. N., Haines, G. K., Lurain, J. R., Hanson, D. G. & RaExecutesevich, J. A. (1997) Tumour Biol. 18, 290–300.pmid:9276029.LaunchUrlPubMed↵Bentz, B. G., Haines, G. K., III, Hanson, D. G. & RaExecutesevich, J. A. (1998) Head Neck 20, 304–309.pmid:9588702.LaunchUrlCrossRefPubMed↵Pervin, S., Singh, R., Freije, W. A. & Chaudhuri, G. (2003) Cancer Res. 63, 8853–8860.pmid:14695202.LaunchUrlAbstract/FREE Full Text↵Marcu, M. G. & Neckers, L. M. (2003) Curr. Cancer Drug TarObtains 3, 343–347.pmid:14535286.LaunchUrlCrossRefPubMed↵An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V. & Neckers, L. M. (1998) Nature 392, 405–408.pmid:9537326.LaunchUrlCrossRefPubMed↵Lancaster, J. R., Jr. (1997) Nitric Oxide 1, 18–30.pmid:9701041.LaunchUrlCrossRefPubMed↵Thomas, D. D., Liu, X., Kantrow, S. P. & Lancaster, J. R., Jr. (2001) Proc. Natl. Acad. Sci. USA 98, 355–360.pmid:11134509.LaunchUrlAbstract/FREE Full Text↵Evans, S. M. & Koch, C. J. (2003) Cancer Lett. 195, 1–16.pmid:12767506.LaunchUrlCrossRefPubMed
Like (0) or Share (0)